These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16964826)

  • 1. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.
    Abecasis AB; Deforche K; Bacheler LT; McKenna P; Carvalho AP; Gomes P; Vandamme AM; Camacho RJ
    Antivir Ther; 2006; 11(5):581-9. PubMed ID: 16964826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
    Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
    Lisovsky I; Schader SM; Martinez-Cajas JL; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2878-85. PubMed ID: 20404123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
    Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Moreau Y; Shafer RW; Van Laethem K; Carvalho AP; Wynhoven B; Cane P; Snoeck J; Clarke J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Shapiro JM; Katzenstein DA; Kantor R; Vandamme AM
    Infect Genet Evol; 2007 Jun; 7(3):382-90. PubMed ID: 17127103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
    Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
    J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
    Marcelin AG; Masquelier B; Descamps D; Izopet J; Charpentier C; Alloui C; Bouvier-Alias M; Signori-Schmuck A; Montes B; Chaix ML; Amiel C; Santos GD; Ruffault A; Barin F; Peytavin G; Lavignon M; Flandre P; Calvez V
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3237-43. PubMed ID: 18625773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.
    Santos AF; Tebit DM; Lalonde MS; Abecasis AB; Ratcliff A; Camacho RJ; Diaz RS; Herchenröder O; Soares MA; Arts EJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2719-25. PubMed ID: 22330918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms.
    Champenois K; Bocket L; Deuffic-Burban S; Cotte L; André P; Choisy P; Yazdanpanah Y
    AIDS; 2008 May; 22(9):1087-9. PubMed ID: 18520355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
    Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL
    J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
    Velazquez-Campoy A; Todd MJ; Vega S; Freire E
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6062-7. PubMed ID: 11353856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
    Soler-Palacín P; Fàbrega A; María López R; Figueras C
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.